Imaging liver cancer blood flow with nitroglycerin during TACE
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests whether adding a drug (nitroglycerin) to a standard liver cancer treatment (TACE) improves the way the drug reaches the tumor. It uses imaging to see changes in blood flow, which might make the treatment more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one liver tumor that has not been treated before.
- You must be 18 or older.
- You must be in good enough health to do light or normal activity (ECOG 0 or 1).
- Your liver and kidney function must be within certain limits (checked with blood tests).
- You must not be taking certain heart or erectile dysfunction medicines (like Nitroglycerin, Viagra, or Avastin).
- If you can have children, you must agree to use effective birth control during the study and for 30 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking for blood markers that may help doctors learn how well TACE treatment is working for liver cancer. You need to be scheduled for TACE and have a follow-up scan to participate.
This study looks at blood tests to see if they can predict how well liver cancer responds to a procedure called TACE. Participation involves giving blood samples and having your normal follow-up scans.
This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).
This study combines a liver-directed procedure called TACE (which blocks blood flow to the tumor and delivers chemotherapy directly to it) with two immunotherapy drugs and a targeted therapy (bevacizumab). The goal is to see if this combination can shrink liver cancer that cannot be surgically removed, without the cancer having spread elsewhere.
This trial tests a combination of an immunotherapy drug (QL1706) and a liver-directed procedure (TACE) before and after surgery for people with liver cancer that is larger or more advanced than the usual transplant criteria. The goal is to see if this approach can help shrink the tumor and improve outcomes.
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.